Archive | Pharmaceutical Law

RSS feed for this section

Technical Highlight: Strengthening the Medicines Regulatory System in Swaziland

Swaziland is one of three remaining countries in the Southern Africa Development Community Region that do not have adequate regulatory and legislative frameworks to control the use, importation, manufacturing, and exportation of medicines. This is in the face of increased incidence of counterfeit medicines in the region; up to 25% of marketed medicines are substandard, and this is up to 64% for antimalarial medicines, according to a study conducted in 2011. Use of counterfeit and substandard medicines increases the burden of disease because of therapeutic failure, exacerbation of disease, and resistance to medicines. Swaziland’s weakness in medicines regulation and limited regulatory enforcement is also exploited by those smuggling prohibited and counterfeit medicines into neighboring countries.

 

Read full story · Comments are closed

Swaziland Pharmaceutical Strategic Plan (2012-2016): Baseline Survey

Swaziland’s Ministry of Health has published its Pharmaceutical Strategic Plan, 2012-2016, serving as a roadmap for the revised national pharmaceutical policy. This report is intended to facilitate the monitoring and evaluation of implementation of the Strategic Plan. The report is a reflection of characteristics of the pharmaceutical sector in 2012.

Read full story · Comments are closed

Assessment of the Regulatory Systems and Capacity of the Directorate General for Drug Administration in Bangladesh

The DGDA invited the USAID-funded SIAPS program to provide support for a comprehensive assessment of the Bangladeshi pharmaceutical regulatory system. The SIAPS program used the Regulatory Systems Assessment Tool (RSAT) to conduct a structured assessment of the DGDA, reviewed more than 50 documents, and conducted interviews with key informants. The assessment also reviewed the DGDA’s Operational Plan for Strengthening of Drug Administration and Management as contained in the Ministry of Health and Family Welfare (MOHFW) Health, Population, and Nutrition Sector Development Program (HPNSDP) strategic plan for 2011-2016.

Read full story · Comments are closed

Haiti Pharmaceutical Sector Technical Assistance Priorities

Download

Access to medicines remains a major issue for the Haitian population. National-level statistics show that less than half the population has acceptable access to medicines. In addition, for those who have access, there is no guarantee of the quality of medicines. As part of the strategy to reform the health system, the MSPP has decided to develop a new NMP. This policy is a commitment from the nation to provide quality pharmaceutical services to the Haitian population on the basis of equity and justice.

Read full story · Comments are closed